Sign Up Today and Learn More About ReCode Therapeutics Stock
Invest in or calculate the value of your shares in ReCode Therapeutics or other pre-IPO companies through EquityZen's platform.
ReCode Therapeutics Stock (REOT)
ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.
About ReCode Therapeutics Stock
Founded
2015
Headquarters
Dallas, TX, US
Industries
Science and Engineering, Health Care, Biotechnology
ReCode Therapeutics Press Mentions
Stay in the know about the latest news on ReCode Therapeutics
Cystic fibrosis: is the next blockbuster a gene therapy?
labiotech • Apr 09, 2025
Lipid nanoparticle compositions and uses thereof
patents • Apr 02, 2025
Compositions and methods for targeted delivery to cells
patents • Apr 02, 2025
Biotech’s ‘Worst Fear’ Comes True as FDA’s Marks Departs, Sending Shares Tumbling
biospace • Apr 01, 2025
mRNA Vaccine and Therapeutics Market Report 2025-2035: 430+ Patents Filed, Signaling Robust Growth in mRNA Intellectual Property
globenewswire • Apr 01, 2025
ReCode Therapeutics Management
Leadership team at ReCode Therapeutics
Co-Founder
Daniel Siegwart
Co-Founder
Philip Thomas
Join now and verify your accreditation status to gain access to:
- ReCode Therapeutics Current Valuation
- ReCode Therapeutics Stock Price
- ReCode Therapeutics Management
- Available deals in ReCode Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- ReCode Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- ReCode Therapeutics Revenue and Financials
- ReCode Therapeutics Highlights
- ReCode Therapeutics Business Model
- ReCode Therapeutics Risk Factors
- ReCode Therapeutics Research Report from SACRA Research
Trading ReCode Therapeutics Stock
How to invest in ReCode Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like ReCode Therapeutics through EquityZen funds. These investments are made available by existing ReCode Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell ReCode Therapeutics stock?
Shareholders can sell their ReCode Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
